2024
Risk of Clade II Mpox Associated with Intimate and Nonintimate Close Contact Among Men Who Have Sex with Men and Transgender Adults — United States, August 2022–July 2023
Chard A, Dalton A, Diallo A, Moulia D, Deputy N, Zecca I, Quilter L, Kachur R, McCollum A, Rowlands J, Britton A, Fisher R, Chai S, Licherdell E, Still W, Morris A, Castilho J, Markus T, Morrow A, Danza P, Hansen A, Ali S, Wegner C, Weber R, Betancourt G, Zipprich J, Sutton M, Pathela P, Hawkins S, Wendel K, Feldstein L. Risk of Clade II Mpox Associated with Intimate and Nonintimate Close Contact Among Men Who Have Sex with Men and Transgender Adults — United States, August 2022–July 2023. MMWR Morbidity And Mortality Weekly Report 2024, 73: 896-902. PMID: 39388387, PMCID: PMC11466375, DOI: 10.15585/mmwr.mm7340a2.Peer-Reviewed Original ResearchConceptsCondomless receptive anal sexReceptive anal sexAnal sexUnited StatesCase-patientsControl patientsAssociated with sexual contactSex practicesSexually active personsTransgenderAssociated with transmissionSexual contactAdjusted oddsMSMMenVaccination coverageActive personsNonintimatesVaccinePatientsMpoxVaccine promotionMultifaceted approachSexIntimate
2023
Estimated Effectiveness of JYNNEOS Vaccine in Preventing Mpox: A Multijurisdictional Case-Control Study — United States, August 19, 2022–March 31, 2023
Dalton A, Diallo A, Chard A, Moulia D, Deputy N, Fothergill A, Kracalik I, Wegner C, Markus T, Pathela P, Still W, Hawkins S, Mangla A, Ravi N, Licherdell E, Britton A, Lynfield R, Sutton M, Hansen A, Betancourt G, Rowlands J, Chai S, Fisher R, Danza P, Farley M, Zipprich J, Prahl G, Wendel K, Niccolai L, Castilho J, Payne D, Cohn A, Feldstein L, Group C, Group C, Saadeh K, Snyder R, Anderson M, Anguiano V, Nadle J, Rothrock G, Jones S, Duval L, Herlihy R, Stringer G, Weber R, Phan Q, Sosa L, Meek J, Lee M, Morrow A, Willut C, Carlson J, Kamis K, Nishiyama M, Simien G, Colasanti J, van der Woude T, Archer R, Finn L, Lam J, Moulton B, Peterson E, Bolan R, Garcia-Lopez G, Como-Sabetti K, Ruff A, Schneider D, Robinson T, Anderson B, Engesser K, McGuire S, Rowe A, Pride C, Mitchell J, Tourkina Y, Cieslak P, Fill M, Wiedeman C, Dumyati G, Felsen C, Lewnard J, Akoko B, Mansilla-Dubon K, Ndi D, Talbot H, Tiwari S, Wyatt D. Estimated Effectiveness of JYNNEOS Vaccine in Preventing Mpox: A Multijurisdictional Case-Control Study — United States, August 19, 2022–March 31, 2023. MMWR Morbidity And Mortality Weekly Report 2023, 72: 553-558. PMID: 37200229, PMCID: PMC10205167, DOI: 10.15585/mmwr.mm7220a3.Peer-Reviewed Original ResearchConceptsAdjusted vaccine effectivenessVaccine effectivenessCase-control studyFull vaccinationEmerging Infections Program sitesEmergency use authorizationDuration of protectionPrevention of smallpoxImmunocompetent participantsImmunocompromised participantsControl patientsImmunization PracticesPartial vaccinationIntradermal injectionSubcutaneous injectionVaccinationMonkeypox casesAdministration routeDrug AdministrationVaccine accessLaboratory capacityTransgender adultsVaccineTransgender personsAdvisory Committee
2022
Early Release - Economic Burden of Reported Lyme Disease in High-Incidence Areas, United States, 2014–2016 - Volume 28, Number 6—June 2022 - Emerging Infectious Diseases journal - CDC
Hook S, Jeon S, Niesobecki S, Hansen A, Meek J, Bjork J, Dorr F, Rutz H, Feldman K, White J, Backenson P, Shankar M, Meltzer M, Hinckley A. Early Release - Economic Burden of Reported Lyme Disease in High-Incidence Areas, United States, 2014–2016 - Volume 28, Number 6—June 2022 - Emerging Infectious Diseases journal - CDC. Emerging Infectious Diseases 2022, 28: 1170-1179. PMID: 35608612, PMCID: PMC9155891, DOI: 10.3201/eid2806.211335.Peer-Reviewed Original ResearchConceptsTotal societal costsSocietal costsLyme diseasePatient costsInfectious Diseases journal - CDCMean patient costMean societal costLyme disease endemic stateTotal patient costsCost-effectiveness analysisDisseminated diseaseProspective studyEarly diagnosisIncidence areaDiseaseEffective preventionProbable diseaseDemographic factorsPrevention methodsComprehensive economic evaluationEconomic evaluationPatientsVaccineIllnessDiagnosis
2021
Evaluating public acceptability of a potential Lyme disease vaccine using a population-based, cross-sectional survey in high incidence areas of the United States
Hook SA, Hansen AP, Niesobecki SA, Meek JI, Bjork JKH, Kough EM, Peterson MS, Schiffman EK, Rutz HJ, Rowe AJ, White JL, Peel JL, Biggerstaff BJ, Hinckley AF. Evaluating public acceptability of a potential Lyme disease vaccine using a population-based, cross-sectional survey in high incidence areas of the United States. Vaccine 2021, 40: 298-305. PMID: 34895785, DOI: 10.1016/j.vaccine.2021.11.065.Peer-Reviewed Original ResearchConceptsLyme disease vaccineDisease vaccineSurvey-weighted descriptive statisticsMultivariable multinomial logistic regression modelsCross-sectional studyLyme disease incidenceHigh incidence areaCross-sectional surveyLogistic regression modelsSafety concernsMultinomial logistic regression modelsVaccine uptakeAdults 45Vaccine parametersVaccine candidatesVaccine attitudesPrevention optionsHealthcare providersWeb-based surveyVaccineSociodemographic characteristicsIncidence areaLyme diseaseDisease incidenceIncidence